Analyzing Champions Oncology (NASDAQ:CSBR) and Azenta (NASDAQ:AZTA)

Champions Oncology (NASDAQ:CSBR) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Valuation and Earnings

This table compares Champions Oncology and Azenta”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42 million	1.22	-$1.17 million	($0.08)	-65.25
Azenta	$593.82 million	2.31	-$55.76 million	($2.76)	-11.35

Champions Oncology has higher earnings, but lower revenue than Azenta. Champions Oncology is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Champions Oncology and Azenta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.87%	-27.48%	-3.84%
Azenta	-20.63%	1.18%	0.97%

Institutional & Insider Ownership

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 46.3% of Champions Oncology shares are held by company insiders. Comparatively, 10.9% of Azenta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Champions Oncology and Azenta, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1	0	0	0	1.00
Azenta	1	2	4	0	2.43

Azenta has a consensus price target of $41.20, suggesting a potential upside of 31.50%. Given Azenta’s stronger consensus rating and higher possible upside, analysts clearly believe Azenta is more favorable than Champions Oncology.

Volatility and Risk

Champions Oncology has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, Azenta has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Summary

Azenta beats Champions Oncology on 10 of the 14 factors compared between the two stocks.

About Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

About Azenta

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.